Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,294,826
  • Shares Outstanding, K 105,188
  • Annual Sales, $ 675,040 K
  • Annual Income, $ 141,210 K
  • EBIT $ 66 M
  • EBITDA $ 56 M
  • 60-Month Beta 0.25
  • Price/Sales 6.60
  • Price/Cash Flow 30.89
  • Price/Book 6.39

Options Overview Details

View History
  • Implied Volatility 72.85% (-9.86%)
  • Historical Volatility 216.70%
  • IV Percentile 53%
  • IV Rank 35.35%
  • IV High 138.94% on 12/15/25
  • IV Low 36.71% on 08/28/25
  • Expected Move (DTE 13) 4.12 (10.10%)
  • Put/Call Vol Ratio 0.54
  • Today's Volume 412
  • Volume Avg (30-Day) 4,624
  • Put/Call OI Ratio 1.39
  • Today's Open Interest 49,104
  • Open Int (30-Day) 49,306
  • Expected Range 36.71 to 44.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.27
  • Number of Estimates 4
  • High Estimate 0.30
  • Low Estimate 0.18
  • Prior Year 0.26
  • Growth Rate Est. (year over year) +3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.80 +20.80%
on 01/20/26
47.06 -13.24%
on 01/28/26
+5.05 (+14.11%)
since 01/06/26
3-Month
32.99 +23.76%
on 12/31/25
89.00 -54.12%
on 12/15/25
-32.23 (-44.11%)
since 11/06/25
52-Week
32.99 +23.76%
on 12/31/25
117.33 -65.20%
on 03/31/25
-27.21 (-39.99%)
since 02/06/25

Most Recent Stories

More News
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

 

CORT : 40.83 (+6.44%)
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

LOS ANGELES , Feb. 5, 2026 /PRNewswire/ -- The DJS Law Group  announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company")...

CORT : 40.83 (+6.44%)
Lost Money on Corcept Therapeutics Incorporated (CORT)? Possible Fraud - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - February 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated")...

CORT : 40.83 (+6.44%)
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Corcept Therapeutics Incorporated (“Corcept”...

CORT : 40.83 (+6.44%)
3 Profitable Stocks with Warning Signs

3 Profitable Stocks with Warning Signs

CORT : 40.83 (+6.44%)
REZI : 36.38 (+4.60%)
OMC : 69.87 (+1.09%)
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT ) investors concerning the Company’s...

CORT : 40.83 (+6.44%)
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT ) on behalf of investors concerning...

CORT : 40.83 (+6.44%)
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm

SAN FRANCISCO , Feb. 2, 2026 /PRNewswire/ -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also...

CORT : 40.83 (+6.44%)
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

LOS ANGELES , Feb. 2, 2026 /PRNewswire/ --  The DJS Law Group  announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company")...

CORT : 40.83 (+6.44%)
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

LOS ANGELES , Feb. 2, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics...

CORT : 40.83 (+6.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 43.72
2nd Resistance Point 42.28
1st Resistance Point 41.56
Last Price 40.83
1st Support Level 39.39
2nd Support Level 37.95
3rd Support Level 37.23

See More

52-Week High 117.33
Fibonacci 61.8% 85.11
Fibonacci 50% 75.16
Fibonacci 38.2% 65.21
Last Price 40.83
52-Week Low 32.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar